Search - tctmd.com

Displaying 261 - 280 of 477

Sort: Relevancy | Date

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

Presenter: Sorin J. Brener, Franz-Josef Neumann, Usman Baber

October 30, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

News Conference News TCT 2015

IBIS-4: Rosuvastatin Tied to Plaque Stability in STEMI

Yael L. Maxwell

October 16, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

$Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!$

Presentation TCT 2015

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!

Presenter: John A. Bittl, Robert A. Harrington, Michael S. Lee

October 12, 2015

Presentation TCT 2015

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin!

Presenter: John A. Bittl, Robert A. Harrington, George D. Dangas

October 12, 2015

Presentation TCT 2015

Is Prolonged Antithrombin Use After Primary PCI in STEMI Beneficial?

Presenter: John A. Bittl, Robert A. Harrington, Mahesh Madhavan

October 12, 2015

Presentation TCT 2015

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Presenter: John A. Bittl, Robert A. Harrington, David Erlinge

October 12, 2015

Presentation TCT 2015

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Presenter: John A. Bittl, Robert A. Harrington, Harvey D. White

October 12, 2015

Presentation TCT 2015

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Presenter: John A. Bittl, Robert A. Harrington, Jorge F. Saucedo

October 12, 2015

Presentation TCT 2015

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Presenter: John A. Bittl, Robert A. Harrington, Philippe Gabriel Steg

October 12, 2015

Presentation TCT 2015

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Presenter: John A. Bittl, Robert A. Harrington, Marco Valgimigli

October 12, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

News Conference News TCT 2015

Robotic Systems to Play Greater Role in Cath Lab of the Future

Todd Neale

October 12, 2015

Advertisement

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

IBIS-4: Rosuvastatin Tied to Plaque Stability in STEMI

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

Discussion Highlights Merits, Limitations of Small Trials

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Unfractionated Heparin!

Debate: Bivalirudin vs Heparin During PCI in Stable CAD? Bivalirudin!

Is Prolonged Antithrombin Use After Primary PCI in STEMI Beneficial?

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

DAPT Study Subanalysis Focuses on EES Subgroup

Robotic Systems to Play Greater Role in Cath Lab of the Future

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content